Literature DB >> 24771911

Use of the Sentinel Lymph Node Technique Compared to Complete Inguino-femoral Lymph Node Removal in Patients with Invasive Vulvar Cancer in Germany.

F Kramer1, H Hertel1, P Hillemanns1.   

Abstract

In the current S2 guidelines, the standard surgical therapy for patients with vulvar cancer also includes inguino-femoral lymphadenectomy. However, in view of the severe side-effects associated with this approach such as problems with wound healing, lymphoceles and lymphoedema, the search is on for alternative treatments that could decrease treatment-associated morbidity and improve patients' quality of life, particularly for node-negative patients. The sentinel lymph node technique is currently the gold standard in the treatment of unifocal breast cancer (clinically negative axilla), and studies on the use of this technique in the treatment of vulvar cancer are promising. To date, the diagnostic accuracy of this method in vulvar cancer has only been evaluated in a single, one-arm, non-randomised, multicentre study. In preparation for a multicentre study, in 2010 we surveyed 41 German hospitals to investigate how often they used the sentinel lymph node technique compared to inguino-femoral lymphadenectomy. The hospitals were grouped according to hospital size and number of patients treated for vulvar cancer. The decision criteria to determine the type of procedure performed were also investigated. Finally, the hospitals were asked whether they would be willing to participate in a prospective clinical study to evaluate the sentinel lymph node technique in patients with vulvar cancer. The majority of surgeons questioned (73 %) already had some experience with this technique in patients with vulvar cancer. In our survey, 27 % of hospitals carried out inguino-femoral lymphadenectomy, 10 % used the sentinel lymph node technique, and 63 % used both methods. In 24 % of hospitals, the standard procedure consisted of the sentinel lymph node technique supplemented by inguino-femoral lymphadenectomy. Only 20 % of the institutions surveyed in our study carried out sentinel lymph node biopsy alone in accordance with the criteria of the consensus recommendations. The majority of the investigated institutions were willing to participate in a randomised prospective clinical study to evaluate the effectiveness of sentinel lymph node sampling in patients with vulvar cancer.

Entities:  

Keywords:  Vulvar cancer; complete inguino-femoral lymphadenectomy; sentinel lymph node dissection

Year:  2013        PMID: 24771911      PMCID: PMC3859150          DOI: 10.1055/s-0032-1328133

Source DB:  PubMed          Journal:  Geburtshilfe Frauenheilkd        ISSN: 0016-5751            Impact factor:   2.915


  19 in total

1.  Groin dissection versus groin radiation in carcinoma of the vulva: a Gynecologic Oncology Group study.

Authors:  F B Stehman; B N Bundy; G Thomas; M Varia; T Okagaki; J Roberts; J Bell; P B Heller
Journal:  Int J Radiat Oncol Biol Phys       Date:  1992       Impact factor: 7.038

2.  In situ and invasive vulvar cancer incidence trends (1973 to 1987).

Authors:  S R Sturgeon; L A Brinton; S S Devesa; R J Kurman
Journal:  Am J Obstet Gynecol       Date:  1992-05       Impact factor: 8.661

3.  Radical vulvectomy and bilateral inguinal lymphadenectomy through separate groin incisions.

Authors:  N F Hacker; R S Leuchter; J S Berek; T W Castaldo; L D Lagasse
Journal:  Obstet Gynecol       Date:  1981-11       Impact factor: 7.661

4.  Inguinal sentinel node dissection versus standard inguinal node dissection in patients with vulvar cancer: A comparison of the size of metastasis detected in inguinal lymph nodes.

Authors:  Katina Robison; Margaret M Steinhoff; C O Granai; Laurent Brard; Walter Gajewski; Richard G Moore
Journal:  Gynecol Oncol       Date:  2005-10-24       Impact factor: 5.482

5.  Inguinofemoral dissection for carcinoma of the vulva: effect of modifications of extent and technique on morbidity and survival.

Authors:  Roman Rouzier; Bassam Haddad; Gil Dubernard; Philippe Dubois; Bernard-Jean Paniel
Journal:  J Am Coll Surg       Date:  2003-03       Impact factor: 6.113

6.  Histopathological work-up and interpretation of sentinel lymph nodes removed for vulvar squamous cell carcinoma.

Authors:  Sigrid Regauer
Journal:  Histopathology       Date:  2009-08       Impact factor: 5.087

7.  Intraepithelial and invasive squamous cell neoplasia of the vulva: trends in incidence, recurrence, and survival rate in Norway.

Authors:  T Iversen; S Tretli
Journal:  Obstet Gynecol       Date:  1998-06       Impact factor: 7.661

8.  Vulvar intraepithelial neoplasia III: a clinical study of the outcome in 113 cases with relation to the later development of invasive vulvar carcinoma.

Authors:  R W Jones; D M Rowan
Journal:  Obstet Gynecol       Date:  1994-11       Impact factor: 7.661

9.  Does T1, N0-1 vulvar cancer treated by vulvectomy but not lymphadenectomy need inguinofemoral radiation?

Authors:  M Manavi; A Berger; E Kucera; N Vavra; H Kucera
Journal:  Int J Radiat Oncol Biol Phys       Date:  1997-07-01       Impact factor: 7.038

Review 10.  SLNB and the importance of micrometastases in vulvar squamous cell carcinoma.

Authors:  Synne Knopp; Jahn M Nesland; Claes Tropé
Journal:  Surg Oncol       Date:  2008-06-16       Impact factor: 3.279

View more
  3 in total

1.  Therapy for Primary Vulvar Carcinoma.

Authors:  D Herr; I Juhasz-Boess; E F Solomayer
Journal:  Geburtshilfe Frauenheilkd       Date:  2014-03       Impact factor: 2.915

Review 2.  Surgical management of squamous cell vulvar cancer without clitoris, urethra or anus involvement.

Authors:  Alpaslan Kaban; Işık Kaban; Selim Afşar
Journal:  Gynecol Oncol Rep       Date:  2017-02-10

3.  Assessment of TSPAN Expression Profile and Their Role in the VSCC Prognosis.

Authors:  Kelly Pedrozo Ferreira; Bruna Cristine de Almeida; Laura Gonzalez Dos Anjos; Glauco Baiocchi; Fernando Augusto Soares; Rafael Malagoli Rocha; Edmund Chada Baracat; Andrey Senos Dobroff; Katia Candido Carvalho
Journal:  Int J Mol Sci       Date:  2021-05-09       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.